Welcome to SAfAIDS
MUTARE, 11 April 2016 (Daily News) - An organisation involved in the fight against HIV and Aids has said stigma, discrimination and the country’s bad laws are hindering efforts to end the epidemic.
HARARE, 06 April 2016 (263chat) - The Zimbabwe Prisons and Correctional Services (ZPCS) has urged policy makers to amend the Health and Prison acts so as to address plights of children living in prisons with their mothers who would have been incarcerated.
HARARE, 06 April 2016 (NewsDay) - Prison officials have lamented overcrowding in correctional facilities which is fuelling sexual violence and posing a serious public health problem.
“Between 2000 and 2015, tuberculosis (TB) prevention, diagnosis and treatment saved 43 million lives. The TB mortality rate has fallen by nearly half. The Millennium Development Goal target of reversing TB incidence has been achieved. But, the fight against this deadly disease is only half-won. This year alone, TB will affect over 9.6 million men, women and children, and 1.5 million people will lose their lives”-UN Secretary General, Ban Ki-moon.
ART has averted over 850,000 HIV-related opportunistic infections in low and middle income countries
BOSTON, 21 March 2016 (aidsmap)- Rollout of antiretroviral therapy (ART) in low and middle income countries has averted over 850,000 cases of HIV-related opportunistic infections at a saving of at least $47 million per year, according to a systematic review and meta-analysis published in Clinical Infectious Diseases. Incidence of opportunistic infections (OIs) declined by between 57-91% in the first year after starting ART, with the greatest reductions in cases of oral thrush, toxoplasmosis and PCP pneumonia.
Researchers say long-lasting injections of an HIV drug could improve adherence to medication regimens, a major challenge in the management of the disease
NORTH CAROLINA, 21 March 2016 (sciencedaily)- Vaginal transmission accounts for the majority of new HIV infections worldwide. Forms of pre-exposure prophylaxis (PrEP) such as vaginal gels and vaginal rings designed to prevent HIV transmission have encountered poor efficacy in human trials due to problems with adherence. In an effort to minimize obstacles to adherence and prevent vaginal HIV transmission, researchers from the division of infectious diseases at the University of North Carolina School of Medicine and collaborators from Merck demonstrated the effectiveness of a new long-acting formulation of the HIV drug raltegravir in animal models.